Division of Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Nat Med. 2010 Mar;16(3):319-23. doi: 10.1038/nm.2089. Epub 2010 Feb 21.
The worldwide diversity of HIV-1 presents an unprecedented challenge for vaccine development. Antigens derived from natural HIV-1 sequences have elicited only a limited breadth of cellular immune responses in nonhuman primate studies and clinical trials to date. Polyvalent 'mosaic' antigens, in contrast, are designed to optimize cellular immunologic coverage of global HIV-1 sequence diversity. Here we show that mosaic HIV-1 Gag, Pol and Env antigens expressed by recombinant, replication-incompetent adenovirus serotype 26 vectors markedly augmented both the breadth and depth without compromising the magnitude of antigen-specific T lymphocyte responses as compared with consensus or natural sequence HIV-1 antigens in rhesus monkeys. Polyvalent mosaic antigens therefore represent a promising strategy to expand cellular immunologic vaccine coverage for genetically diverse pathogens such as HIV-1.
全球范围内 HIV-1 的多样性给疫苗开发带来了前所未有的挑战。迄今为止,源自天然 HIV-1 序列的抗原仅在非人类灵长类动物研究和临床试验中引发了有限范围的细胞免疫反应。相比之下,多价“嵌合”抗原旨在优化针对全球 HIV-1 序列多样性的细胞免疫覆盖。在这里,我们表明,由重组、复制缺陷型腺病毒血清型 26 载体表达的嵌合 HIV-1 Gag、Pol 和 Env 抗原明显增强了广度和深度,而不会影响抗原特异性 T 淋巴细胞反应的幅度,与恒河猴中的共识或天然序列 HIV-1 抗原相比。因此,多价嵌合抗原代表了一种有前途的策略,可以扩大针对遗传多样化病原体(如 HIV-1)的细胞免疫疫苗覆盖范围。